Efficacy and safety of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies after highly emetogenic chemotherapy

Efficacy and safety of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies after highly emetogenic chemotherapy - Efficacy and safety of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies after highly emetogenic chemotherapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005624

Enrollment

100

Registered

2011-05-22

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancies

Interventions

Aprepitant on days 1 to 3 Granisetron on day 1 Dexamethasone on days 1 to 4 Granisetron on day 1 Dexamethasone on days 1 to 4

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient can take Aprepitant for internal use.

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity for Aprepitant. 2.Patient is receiving treatment with pimozide.

Design outcomes

Primary

Measure	Time frame
The proportion of patients with no emesis and no nausea in overall phase (0-120 hours after chemotherapy)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026